Evidence map›Paper›PMID 39367269›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2024

Suppressing the expression of steroidogenic acute regulatory protein (StAR) in the myocardium by spironolactone contributes to the improvement of right ventricular remodeling in pulmonary arterial hypertension.

Hideki Imano, Tetsuya Hayashi, Atsuo Nomura, Saori Tanaka, Yuka Kohda, Takehiro Yamaguchi, Yasukatsu Izumi, Minoru Yoshiyama, Yoshinobu Hirose, Keiko Ohta-Ogo and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Hideki ImanoDepartment of Pharmacotherapeutics and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Tetsuya HayashiDepartment of Pharmacotherapeutics and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Atsuo NomuraDepartment of Pharmacology, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan.
Saori TanakaDepartment of Pharmacotherapeutics and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Yuka KohdaDepartment of Pharmacotherapeutics and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Takehiro YamaguchiDepartment of Pharmacology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Yasukatsu IzumiDepartment of Pharmacology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Minoru YoshiyamaDepartment of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Yoshinobu HiroseDepartment of Pathology, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Keiko Ohta-OgoDepartment of Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan.
Hatsue Ishibashi-UedaDepartment of Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan.
Ryuji KatoDepartment of Pharmacotherapeutics and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan. ryuji.kato@ompu.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary arterial hypertension (PAH) is a progressive condition that frequently leads to right ventricular (RV) remodeling. Aldosterone promotes vascular and RV remodeling. The upregulation of steroidogenic acute regulatory protein (StAR) stimulates aldosterone synthesis. However, the expression of StAR in the myocardium under PAH conditions remains unknown. To investigate the expression of StAR in the myocardium and its association with RV remodeling in PAH, utilizing spironolactone as a treatment. A PAH model was created using male Sprague-Dawley rats, which received a subcutaneous injection of Sugen5416 (20 mg/kg) and were exposed to hypoxia (10% O

Indexed as

MyocardiumPhosphoproteinsPulmonary Arterial HypertensionRats, Sprague-DawleySpironolactoneVentricular RemodelingAldosteroneAnimalsCell LineMaleMineralocorticoid Receptor AntagonistsRatsSteroidogenic Acute Regulatory ProteinAldosteroneMineralocorticoid Receptor AntagonistsPhosphoproteinsSpironolactoneSteroidogenic Acute Regulatory ProteinMyocardial aldosterone productionPulmonary arterial hypertensionRight ventricular remodelingSpironolactoneSteroidogenic acute regulatory protein

Identifiers

PMID39367269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.